Impact of Ocular Surface Disease Treatment in Patients with Glaucoma

Ana Luiza Mylla Boso, Erica Gasperi, Leticia Fernandes, Vital Paulino Costa, Monica Alves Department of Ophthalmology and Otorhinolaryngology, Faculty of Medical Sciences, University of Campinas (UNICAMP), Campinas, BrazilCorrespondence: Ana Luiza Mylla BosoDepartment of Ophthalmology and Otorhinola...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mylla Boso AL, Gasperi E, Fernandes L, Costa VP, Alves M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	ocular surface disease glaucoma preservative keratograph benzalkonium chloride Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/552c9dcb71f4444bbb29957e38784b07
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:552c9dcb71f4444bbb29957e38784b07
record_format	dspace
spelling	oai:doaj.org-article:552c9dcb71f4444bbb29957e38784b072021-12-02T09:39:38ZImpact of Ocular Surface Disease Treatment in Patients with Glaucoma1177-5483https://doaj.org/article/552c9dcb71f4444bbb29957e38784b072020-01-01T00:00:00Zhttps://www.dovepress.com/impact-of-ocular-surface-disease-treatment-in-patients-with-glaucoma-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Ana Luiza Mylla Boso, Erica Gasperi, Leticia Fernandes, Vital Paulino Costa, Monica Alves Department of Ophthalmology and Otorhinolaryngology, Faculty of Medical Sciences, University of Campinas (UNICAMP), Campinas, BrazilCorrespondence: Ana Luiza Mylla BosoDepartment of Ophthalmology and Otorhinolaryngology, Faculty of Medical Sciences, University of Campinas, Cidade Universitária Zeferino Vaz - Barão Geraldo, Campinas, SP 13083-970, BrazilTel/Fax +55-19 3521 7396Email analuizaamb@gmail.comPurpose: Chronic topical treatment for glaucoma may lead to Ocular Surface Disease (OSD). This study aimed to evaluate: (1) the prevalence of OSD in glaucoma patients under topical treatment, quantifying symptoms and objective ocular surface parameters and (2) the impact of ocular surface treatment on OSD and IOP control.Methods: Patients with primary open angle or primary angle closure glaucoma under topical treatment for at least 6 months were enrolled in the study. Patients underwent symptom screening with the ocular surface disease index (OSDI) questionnaire, assessment of objective ocular surface parameters, ocular surface staining and Schirmer test. A treatment for OSD with eyelid hygiene, fluorometholone acetate 0.1%, preservative-free lubricants, free-acid supplementation and oral tetracyclin derivate was started, and the same evaluation was performed.Results: In our sample (n=19), 73.68% of the patients reported severe symptoms of dry eye disease, with OSDI scores higher than 33 at baseline. Tear film instability was found in 50% of patients, while 23.53% had severe meibomian gland abnormalities. Fluorescein and lissamine green stainings were abnormal in 88.24% and 82.35% of patients, respectively. After ocular surface treatment, statistically significant improvement was found in best-corrected visual acuity (p=0.0003), OSDI score (p< 0.0001), bulbar redness (p=0.0196) and fluorescein staining (p< 0.0001.) Mean IOP following OSD treatment reduced − 1.59 mmHg from baseline in the left eye (p=0.0510).Conclusion: The prevalence of OSD signs and symptoms was high in glaucoma patients under medical treatment. Short-term OSD treatment may improve ocular surface disease and IOP control, with no need to discontinue glaucoma medications.Keywords: ocular surface disease, glaucoma, preservative, keratograph, benzalkonium chlorideMylla Boso ALGasperi EFernandes LCosta VPAlves MDove Medical Pressarticleocular surface diseaseglaucomapreservativekeratographbenzalkonium chlorideOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 103-111 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	ocular surface disease glaucoma preservative keratograph benzalkonium chloride Ophthalmology RE1-994
spellingShingle	ocular surface disease glaucoma preservative keratograph benzalkonium chloride Ophthalmology RE1-994 Mylla Boso AL Gasperi E Fernandes L Costa VP Alves M Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
description	Ana Luiza Mylla Boso, Erica Gasperi, Leticia Fernandes, Vital Paulino Costa, Monica Alves Department of Ophthalmology and Otorhinolaryngology, Faculty of Medical Sciences, University of Campinas (UNICAMP), Campinas, BrazilCorrespondence: Ana Luiza Mylla BosoDepartment of Ophthalmology and Otorhinolaryngology, Faculty of Medical Sciences, University of Campinas, Cidade Universitária Zeferino Vaz - Barão Geraldo, Campinas, SP 13083-970, BrazilTel/Fax +55-19 3521 7396Email analuizaamb@gmail.comPurpose: Chronic topical treatment for glaucoma may lead to Ocular Surface Disease (OSD). This study aimed to evaluate: (1) the prevalence of OSD in glaucoma patients under topical treatment, quantifying symptoms and objective ocular surface parameters and (2) the impact of ocular surface treatment on OSD and IOP control.Methods: Patients with primary open angle or primary angle closure glaucoma under topical treatment for at least 6 months were enrolled in the study. Patients underwent symptom screening with the ocular surface disease index (OSDI) questionnaire, assessment of objective ocular surface parameters, ocular surface staining and Schirmer test. A treatment for OSD with eyelid hygiene, fluorometholone acetate 0.1%, preservative-free lubricants, free-acid supplementation and oral tetracyclin derivate was started, and the same evaluation was performed.Results: In our sample (n=19), 73.68% of the patients reported severe symptoms of dry eye disease, with OSDI scores higher than 33 at baseline. Tear film instability was found in 50% of patients, while 23.53% had severe meibomian gland abnormalities. Fluorescein and lissamine green stainings were abnormal in 88.24% and 82.35% of patients, respectively. After ocular surface treatment, statistically significant improvement was found in best-corrected visual acuity (p=0.0003), OSDI score (p< 0.0001), bulbar redness (p=0.0196) and fluorescein staining (p< 0.0001.) Mean IOP following OSD treatment reduced − 1.59 mmHg from baseline in the left eye (p=0.0510).Conclusion: The prevalence of OSD signs and symptoms was high in glaucoma patients under medical treatment. Short-term OSD treatment may improve ocular surface disease and IOP control, with no need to discontinue glaucoma medications.Keywords: ocular surface disease, glaucoma, preservative, keratograph, benzalkonium chloride
format	article
author	Mylla Boso AL Gasperi E Fernandes L Costa VP Alves M
author_facet	Mylla Boso AL Gasperi E Fernandes L Costa VP Alves M
author_sort	Mylla Boso AL
title	Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
title_short	Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
title_full	Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
title_fullStr	Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
title_full_unstemmed	Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
title_sort	impact of ocular surface disease treatment in patients with glaucoma
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/552c9dcb71f4444bbb29957e38784b07
work_keys_str_mv	AT myllabosoal impactofocularsurfacediseasetreatmentinpatientswithglaucoma AT gasperie impactofocularsurfacediseasetreatmentinpatientswithglaucoma AT fernandesl impactofocularsurfacediseasetreatmentinpatientswithglaucoma AT costavp impactofocularsurfacediseasetreatmentinpatientswithglaucoma AT alvesm impactofocularsurfacediseasetreatmentinpatientswithglaucoma
_version_	1718398066102370304

Impact of Ocular Surface Disease Treatment in Patients with Glaucoma

Ejemplares similares